Browsing Tag
elacestrant
5 posts
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
June 10, 2025
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.
June 9, 2025
Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment…
December 9, 2023
Menarini’s ORSERDU gets CHMP positive opinion in advanced breast cancer
The Menarini Group and its subsidiary, Stemline Therapeutics Inc., have received a favorable opinion from the European Medicines…
July 22, 2023
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for…
February 1, 2023